Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, Julie R., Tykodi, Scott S., Chow, Laura Q.M., Hwu, Wen-Jen, Topalian, Suzanne L., Hwu, Patrick, Drake, Charles G., Camacho, Luis H. +18 more·2012·New England Journal of Medicine
DOI 10.1056/nejmoa1200694

Cited by (1,051)

Items 201–300 of 1,051

  1. Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
    Aleix Prat, Bárbara Adamo, Maggie C.U. Cheang, Carey K. Anders, LA Carey, Charles M. Perou · 2013 · The Oncologist
  2. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
    Siwen Hu‐Lieskovan, Stephen Mok, Blanca Homet Moreno, Jennifer Tsoi, Lídia Robert, Lucas Goedert, Elaine M. Pinheiro, Richard Chikara Koya, Thomas G. Graeber, Begoña Comı́n-Anduix et al. · 2015 · Science Translational Medicine
  3. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
    Ignacio Garrido‐Laguna, Manuel M. Hidalgo · 2015 · Nature Reviews Clinical Oncology
  4. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
    Lisa Zimmer, Simone M. Goldinger, Lars Hofmann, Carmen Loquai, Selma Ugurel, Ioannis Thomas, Maria Isabel Schmidgen, Ralf Gutzmer, Jochen Sven Utikal, Daniela Göppner et al. · 2016 · European Journal of Cancer
  5. PD-1/PD-L1 inhibitors
    Joel Chaim Sunshine, Janis Marie Taube · 2015 · Current Opinion in Pharmacology
  6. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
    Simone E. Muenst, A. R. Schaerli, Feng Gao, Silvio Däster, Emanuele Trella, Raoul Andre Droeser, Manuele Giuseppe Muraro, Paul Zajac, Rosanna Zanetti, William E. Gillanders et al. · 2014 · Breast Cancer Research and Treatment
  7. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
    Bruno Bockorny, Valerya Semenisty, Teresa Mercade Macarulla, Erkut Hasan Borazanci, Brian Matthew Wolpin, Salomon Marcello Stemmer, Talia Golan, Ravit Geva, Mitesh J. Borad, Katrina Sophia Pedersen et al. · 2020 · Nature Medicine
  8. The pharmacology of second-generation chimeric antigen receptors
    Sjoukje J. C. van der Stegen, Mohamad Hamieh, Michel Sadelain · 2015 · Nature Reviews Drug Discovery
  9. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
    Paul C. Tumeh, Matthew David Hellmann, Omid Hamid, Katy K. Tsai, Kimberly Leticia Loo, Matthew A. Gubens, Michael D. Rosenblum, Christina L. Harview, Janis Marie Taube, Nathan R. Handley et al. · 2017 · Cancer Immunology Research
  10. DNA mismatch repair in cancer
    Marina Baretti, Dung Thi Le · 2018 · Pharmacology & Therapeutics
  11. Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer
    Nina G. Steele, Eileen S. Carpenter, Samantha B. Kemp, Veerin R. Sirihorachai, Stephanie The, Lawrence Delrosario, Jenny Lazarus, El-ad David Amir, Valerie Gunchick, Carlos E. Espinoza et al. · 2020 · Nature Cancer
  12. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
    Hoos, Axel · 2016 · Nature Reviews Drug Discovery
  13. Cutaneous melanoma
    Alexander M.M. Eggermont, Alan Spatz, Caroline Robert · 2013 · The Lancet
  14. Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
    Eric R. Lutz, Annie A. Wu, Elaine O. Bigelow, Rajni B Sharma, Guanglan Mo, Kevin C. Soares, Sara Solt, Alvin Dorman, Anthony Wamwea, Allison Yager et al. · 2014 · Cancer Immunology Research
  15. Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
    Kishton, Rigel J., Sukumar, Madhusudhanan, Restifo, Nicholas P. · 2017 · Cell Metabolism
  16. CD4 and CD8 T lymphocyte interplay in controlling tumor growth
    Dmitrij Ostroumov, Nora Fekete-Drimusz, Michael Saborowski, Florian Kühnel, Norman Woller · 2017 · Cellular and Molecular Life Sciences
  17. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
    Martens, Alexander, Wistuba-Hamprecht, Kilian, Foppen, Marnix Geukes, Yuan, Jianda, Postow, Michael A., Wong, Phillip, Romano, Emanuela, Khammari, Amir, Dreno, Brigitte, Capone, Mariaelena et al. · 2016 · Clinical Cancer Research
  18. Network Analysis Reveals Centrally Connected Genes and Pathways Involved in CD8+ T Cell Exhaustion versus Memory
    Travis A. Doering, Alison Crawford, Jill Angelosanto, Michael Paley, Carly G.K. Ziegler, E. John Wherry · 2012 · Immunity
  19. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
    Eléonora De Martin, Jean‐Marie Michot, Barbara Papouin, Stéphane Champiat, Christine Mateus, Olivier Lambotte, Bruno Roche, Térésa Antonini, Audrey Coilly, Salim Laghouati et al. · 2018 · Journal of Hepatology
  20. Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
    Evan J. Lipson, William Howard Sharfman, Charles G. Drake, IRA S. WOLLNER, Janis Marie Taube, Robert A. Anders, Haiying Xu, Sheng Yao, Alice Pons, Lieping Chen et al. · 2012 · Clinical Cancer Research
  21. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
    Krzysztof M. Żak, Radosław Kitel, Sara Przetocka, Przemysław Golik, Katarzyna Guzik, Bogdan Musielak, Alexander S. S. Dömling, Grzegorz Dubin, Tad A. Holak · 2015 · Structure
  22. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
    Hao Zhang, Ziyu Dai, Wantao Wu, Zeyu Wang, Nan Zhang, Liyang Zhang, Wenjing Zeng, Zhixiong Liu, Quan Cheng · 2021 · Journal of Experimental & Clinical Cancer Research
  23. Revisiting the PD-1 pathway
    Nikolaos Patsoukis, Qi Wang, Laura Strauss, Vassiliki A. Boussiotis · 2020 · Science Advances
  24. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
    Weber, Jeffrey S., Kudchadkar, Ragini Reiney, Yu, Bin, Gallenstein, Donna, Horak, Christine E., Inzunza, H. David, Zhao, Xiuhua, Martinez, Alberto J., Wang, Wenshi, Gibney, Geoffrey et al. · 2013 · Journal of Clinical Oncology
  25. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
    Loi, Sherene, Dushyanthen, Sathana, Beavis, Paul A., Salgado, Roberto, Denkert, Carsten, Savas, Peter, Combs, Susan, Rimm, David L., Giltnane, Jennifer M., Estrada, Monica V. et al. · 2016 · Clinical Cancer Research
  26. The gut microbiota influences anticancer immunosurveillance and general health
    Routy, Bertrand, Gopalakrishnan, Vancheswaran, Daillère, Romain, Zitvogel, Laurence, Wargo, Jennifer A., Kroemer, Guido · 2018 · Nature Reviews Clinical Oncology
  27. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
    Luoyan Ai, Antao Xu, Jie Xu · 2020 · Advances in experimental medicine and biology
  28. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response
    Mario Sznol, Lieping Chen · 2013 · Clinical Cancer Research
  29. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements
    Nishino, Mizuki, Giobbie-Hurder, Anita, Gargano, Maria, Suda, Margaret, Ramaiya, Nikhil H., Hodi, F. Stephen · 2013 · Clinical Cancer Research
  30. PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
    Haidong Tang, Yong Liang, Robert A. Anders, Janis Marie Taube, Xiangyan Qiu, Aditi Mulgaonkar, Xin Liu, Susan M. Harrington, Jingya Guo, Yangchun Xin et al. · 2018 · Journal of Clinical Investigation
  31. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
    Roberta Zappasodi, Taha Merghoub, Jedd D. Wolchok · 2018 · Cancer Cell
  32. Adipocyte and lipid metabolism in cancer drug resistance
    Yihai Cao · 2019 · Journal of Clinical Investigation
  33. Roles of regulatory T cells in cancer immunity
    Yoshiko Takeuchi, Hiroyoshi Nishikawa · 2016 · International Immunology
  34. Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
    Zoran Gatalica, Carrie Snyder, Todd Maney, Anatole Ghazalpour, Daniel A. Holterman, Nianqing Xiao, Peggy Overberg, Inga Rose, Gargi Dan Basu, Semir Vranić et al. · 2014 · Cancer Epidemiology Biomarkers & Prevention
  35. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
    Mihaela Angelova, Pornpimol Charoentong, Hubert Hackl, Maria L Fischer, René Snajder, Anne Krogsdam, Maximilian J. Waldner, Gabriela Bindea, Bernhard Mlecnik, Jérôme Galon et al. · 2015 · Genome biology
  36. VISTA is an immune checkpoint molecule for human T cells
    Lines, J. Louise, Pantazi, Eirini, Mak, Justin, Sempere, Lorenzo F., Wang, Li, O'Connell, Samuel, Ceeraz, Sabrina, Suriawinata, Arief A., Yan, Shaofeng, Ernstoff, Marc S. et al. · 2014 · Cancer Research
  37. Immune Modulation in Cancer with Antibodies
    David B. Page, Michael A. Postow, Margaret K. Callahan, James Patrick Allison, Jedd D. Wolchok · 2013 · Annual Review of Medicine
  38. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
    Gregory Lawrence Beatty, Mark H. O’Hara, Simon Francis Lacey, Drew A. Torigian, Farzana Nazimuddin, Fang Chen, Irina M. Kulikovskaya, Michael C. Soulen, Maureen McGarvey, Anne Marie Nelson et al. · 2018 · Gastroenterology
  39. Prognostic and predictive value of PDL1 expression in breast cancer
    Renaud Sabatier, Pascal Finetti, Émilie Mamessier, José Adélaı̈de, Max Chaffanet, Hamid Raza Ali, Patrice Viens, Carlos Caldas, Daniel Birnbaum, François Bertucci · 2014 · Oncotarget
  40. Role of the Tumor Microenvironment in Breast Cancer
    Savas Deniz Soysal, Alexandar Tzankov, Simone E. Muenst · 2015 · Pathobiology
  41. Design and development of therapies using chimeric antigen receptor‐expressing T cells
    Gianpietro Dotti, Stephen M Gottschalk, Barbara Savoldo, Malcolm K. Brenner · 2013 · Immunological Reviews
  42. Radiotherapy combination opportunities leveraging immunity for the next oncology practice
    Fernanda Gabriela Herrera, Jean Bourhis, George Coukos · 2016 · CA A Cancer Journal for Clinicians
  43. PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
    Fatemeh Karimi Dermani, Pouria Samadi, Golebagh Rahmani, Alisa Khodadadi Kohlan, Rezvan Najafi · 2018 · Journal of Cellular Physiology
  44. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
    Nicolás A. Giraldo, Étienne Becht, Franck Pagès, Georgios P. Skliris, Virginie Verkarre, Yann Alexandre Vano, A. Méjean, Nicolas Saint-Aubert, Laetitia Lacroix, Ivo Natario et al. · 2015 · Clinical Cancer Research
  45. The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes
    Huang, Qizhao, Wu, Xia, Wang, Zhiming, Chen, Xiangyu, Wang, Lisha, Lu, Yijun, Xiong, Dan, Liu, Qiao, Tian, Yuhan, Lin, Huayu et al. · 2022 · Cell
  46. Drug development in the era of precision medicine
    Dugger, Sarah A., Platt, Adam, Goldstein, David B. · 2018 · Nature Reviews Drug Discovery
  47. Pembrolizumab (Keytruda)
    Gin Wai Kwok, Thomas C. C. Yau, Joanne Wing Yan Chiu, Eric Tse, Yok‐Lam Kwong · 2016 · Human Vaccines & Immunotherapeutics
  48. PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
    Elise A. Chong, Jan Joseph Melenhorst, Simon Francis Lacey, David E Ambrose, Vanessa E. Gonzalez, Bruce L. Levine, Carl H. June, Stephen J. Schuster · 2016 · Blood
  49. OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
    Brendan D. Curti, Magdalena Kovacsovics-Bankowski, Nicholas P. Morris, Edwin Walker, Lana Chisholm, Kevin Floyd, Joshua M. Walker, Iliana L. Gonzalez, Tanisha L. Meeuwsen, Bernard A. Fox et al. · 2013 · Cancer Research
  50. COX2/mPGES1/PGE <sub>2</sub> pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
    Prima, Victor, Kaliberova, Lyudmila N., Kaliberov, Sergey, Curiel, David T., Kusmartsev, Sergei · 2017 · Proceedings of the National Academy of Sciences
  51. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
    Aaron J. Grossberg, Linda Chi Hang Chu, Christopher R. Deig, Eliot K. Fishman, William L. Hwang, Anirban Maitra, Daniel L. Marks, Arnav Mehta, Nima Nabavizadeh, Diane M. Simeone et al. · 2020 · CA A Cancer Journal for Clinicians
  52. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
    Michael Orth, Philipp Metzger, Sabine Gerum, Julia V. Mayerle, Günter Schneider, Claus Belka, Maximilian Schnurr, Kirsten Lauber · 2019 · Radiation Oncology
  53. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
    Liu, Xinjian, Bao, Xuhui, Hu, Mengjie, Chang, Hanman, Jiao, Meng, Cheng, Jin, Xie, Liyi, Huang, Qian, Li, Fang, Li, Chuan-Yuan · 2020 · Nature
  54. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
    Mario Sznol, Lieping Chen · 2013 · Clinical Cancer Research
  55. VISTA Regulates the Development of Protective Antitumor Immunity
    Isabelle Le Mercier, Wenna Chen, Janet Louise Lines, Maria Day, Jiannan Li, Petra A. Sergent, Randolph J. Noelle, Li Lily Wang · 2014 · Cancer Research
  56. The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
    Jiang, Xiaofeng, Zhou, Jun, Giobbie-Hurder, Anita, Wargo, Jennifer, Hodi, F. Stephen · 2013 · Clinical Cancer Research
  57. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma
    Julien Caldéraro, Florent Petitprez, Étienne Becht, Alexis Laurent, Théo Z. Hirsch, Benoı̂t Rousseau, Alain Luciani, Giuliana Amaddeo, Jonathan Derman, Cécile Charpy et al. · 2018 · Journal of Hepatology
  58. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma
    Winograd, Rafael, Byrne, Katelyn T., Evans, Rebecca A., Odorizzi, Pamela M., Meyer, Anders R.L., Bajor, David L., Clendenin, Cynthia, Stanger, Ben Z., Furth, Emma E., Wherry, E. John et al. · 2015 · Cancer Immunology Research
  59. Role of PD-1 during effector CD8 T cell differentiation
    Eunseon Ahn, Koichi Araki, Masao Hashimoto, Weiyan Li, James L. Riley, Jeanne Cheung, Arlene H. Sharpe, Gordon James Freeman, Bryan A. Irving, Rafi Ahmed · 2018 · Proceedings of the National Academy of Sciences
  60. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
    Panagiotis Sarantis, Evangelos Koustas, Adriana Papadimitropoulou, Athanasios G. Papavassiliou, Michalis V. Karamouzis · 2020 · World Journal of Gastrointestinal Oncology
  61. Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
    Haidong Tang, Yang Wang, Lukasz K. Chlewicki, Yuan Zhang, Jingya Guo, Wei Ping Liang, Jieyi Wang, Xiaoxiao Wang, Yang‐Xin Fu · 2016 · Cancer Cell
  62. Activation of STING-dependent innate immune signaling by s-phase-specific DNA damage in breast cancer
    Parkes, Eileen E., Walker, Steven M., Taggart, Laura E., McCabe, Nuala, Knight, Laura A., Wilkinson, Richard, McCloskey, Karen D., Buckley, Niamh E., Savage, Kienan I., Salto-Tellez, Manuel et al. · 2017 · Journal of the National Cancer Institute
  63. Targeting T Cell Co-receptors for Cancer Therapy
    Margaret K. Callahan, Michael Andrew Postow, Jedd D. Wolchok · 2016 · Immunity
  64. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells
    Pamela M. Odorizzi, Kristen E. Pauken, Michael Paley, Arlene H. Sharpe, E. John Wherry · 2015 · The Journal of Experimental Medicine
  65. Immunotherapy and Prevention of Pancreatic Cancer
    Alexander H. Morrison, Katelyn T. Byrne, Robert H. Vonderheide · 2018 · Trends in cancer
  66. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
    Pengfei Wang, Yang Chen, Siying Song, Tingjian Wang, Wenjun Ji, Shouwei Li, Ning Liu, Changxiang Yan · 2017 · Frontiers in Pharmacology
  67. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
    Benjamin Boyerinas, Caroline Jochéms, Massimo Claudio Fantini, Christopher Ryan Heery, James L. Gulley, Kwong Yok Tsang, Jeffrey Schlom · 2015 · Cancer Immunology Research
  68. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
    Junichi Kiyasu, Hiroaki Miyoshi, Akie Hirata, Fumiko Arakawa, Ayako Ichikawa, Daisuke Niino, Yasuo Sugita, Yuji Yufu, Ilseung Choi, Yasunobu Abe et al. · 2015 · Blood
  69. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer
    Samarth Hegde, Varintra E. Lander, Brett H. Herzog, Chong Zuo, Marcus A. Breden, Brett L. Knolhoff, Graham D. Hogg, Jack Pengfei Tang, John M. Baer, Cedric Mpoy et al. · 2020 · Cancer Cell
  70. Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
    Rituparna Das, Rakesh Verma, Mario Sznol, Chandra Sekhar Boddupalli, Scott N. Gettinger, Harriet M. Kluger, Margaret K. Callahan, Jedd D. Wolchok, Ruth Halaban, Madhav V. Dhodapkar et al. · 2014 · The Journal of Immunology
  71. PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
    Aaron Michael Goodman, Sandip Pravin Patel, Razelle Kurzrock · 2016 · Nature Reviews Clinical Oncology
  72. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
    Meng‐Ling Wu, Qianrui Huang, Yao Xie, Xuyi Wu, Hongbo Ma, Yiwen Zhang, Yong Xia · 2022 · Journal of Hematology & Oncology
  73. PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
    Salmaninejad, Arash, Valilou, Saeed Farajzadeh, Shabgah, Arezoo Gowhari, Aslani, Saeed, Alimardani, Malihe, Pasdar, Alireza, Sahebkar, Amirhossein · 2019 · Journal of Cellular Physiology
  74. Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
    Bertrand Allard, Sandra Pommey, Mark John Smyth, John Stagg · 2013 · Clinical Cancer Research
  75. Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
    Yu-Fang Shi, L. Du, Liang-Yu Lin, Ying Wang · 2016 · Nature reviews. Drug discovery
  76. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
    Miguel F. Sanmamed, José Luis Perez‐Gracia, Kurt Alex Schalper, Juan Pablo Fusco, Álvaro González, Maria Esperanza Rodriguez-Ruiz, Carmen Oñate, G. Perez, Carlos Alfaro, Salvador Martín‐Algarra et al. · 2017 · Annals of Oncology
  77. Ovarian cancer: Current status and strategies for improving therapeutic outcomes
    Ashwin Chandra, Cima Pius, Madiha Nabeel, Maya P. Nair, Jamboor K. Vishwanatha, Sarfraz Ahmad, Riyaz M. Basha · 2019 · Cancer Medicine
  78. Interleukin-17–induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer
    Yu Zhang, Vidhi Chandra, Erick Marcelo Riquelme, Prasanta Dutta, Pompeyo R. Quesada, Amanda I. Rakoski, Michelle Annabel Zoltan, Nivedita Arora, Seyda Baydogan, William T. Horne et al. · 2020 · The Journal of Experimental Medicine
  79. In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
    Kurt Alex Schalper, Vamsidhar Velcheti, Daniel E Carvajal, Hallie Wimberly, Jason Robert Brown, Lajos Pusztai, David L. Rimm · 2014 · Clinical Cancer Research
  80. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
    Luisa Carbognin, Sara Pilotto, Michèle Milella, Vanja Vaccaro, Matteo Brunelli, Anna Caliò, Federica Cuppone, Isabella Sperduti, Diana Giannarelli, Marco Chilosi et al. · 2015 · PLoS ONE
  81. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
    Woods, David M., Sodré, Andressa L., Villagra, Alejandro, Sarnaik, Amod, Sotomayor, Eduardo M., Weber, Jeffrey · 2015 · Cancer Immunology Research
  82. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer
    Liu, Baolin, Hu, Xueda, Feng, Kaichao, Gao, Ranran, Xue, Zhiqiang, Zhang, Sujie, Zhang, Yuanyuan, Corse, Emily, Hu, Yi, Han, Weidong et al. · 2021 · Nature Cancer
  83. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
    Idit Sagiv-Barfi, Holbrook E K Kohrt, Debra Katherine Czerwinski, Patrick P. Ng, Betty Y Chang, Ronald Levy · 2015 · Proceedings of the National Academy of Sciences
  84. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
    Balachandran, Vinod P., Beatty, Gregory L., Dougan, Stephanie K. · 2019 · Gastroenterology
  85. Agonistic CD40 Antibodies and Cancer Therapy
    Robert H. Vonderheide, Martin J. Glennie · 2013 · Clinical Cancer Research
  86. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
    Krzysztof M. Żak, P. Grudnik, Katarzyna Guzik, Bartosz J. Zieba, Bogdan Musielak, Alexander S. S. Dömling, Grzegorz Dubin, Tad A. Holak · 2016 · Oncotarget
  87. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
    Julien Caldéraro, Benoı̂t Rousseau, Giuliana Amaddeo, Marion Mercey-Ressejac, Cécile Charpy, Charlotte E. Costentin, Alain Luciani, Elie‐Serge Zafrani, Alexis Laurent, Daniel Azoulay et al. · 2016 · Hepatology
  88. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
    Philippe A. Armand, Arnon Nagler, Edie A. Weller, Steven Michael Devine, David Avigan, Yi‐Bin Chen, Mark Stefan Kaminski, H. Kent Holland, Jane N. Winter, James R. Mason et al. · 2013 · Journal of Clinical Oncology
  89. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
    Ruscetti, Marcus, Morris, John P., Mezzadra, Riccardo, Russell, James, Leibold, Josef, Romesser, Paul B., Simon, Janelle, Kulick, Amanda, Ho, Yu-jui, Fennell, Myles et al. · 2020 · Cell
  90. The emerging role of epigenetic therapeutics in immuno-oncology
    Topper, Michael J., Vaz, Michelle, Marrone, Kristen A., Brahmer, Julie R., Baylin, Stephen B. · 2020 · Nature Reviews Clinical Oncology
  91. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
    David F. McDermott, Charles G. Drake, Mario Sznol, Toni K. Choueiri, John D. Powderly, David Carl Smith, Julie Renee Brahmer, Richard D. Carvajal, Hans J. Hammers, Igor J. Puzanov et al. · 2015 · Journal of Clinical Oncology
  92. Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
    Yanyan Lou, Lixia Diao, Edwin Roger Parra, Warren L. Denning, Limo Chen, You Hong Fan, Lauren A. Byers, Jing Wang, Vassiliki A. Papadimitrakopoulou, Carmen Behrens et al. · 2016 · Clinical Cancer Research
  93. PD-L1 Expression in Lung Cancer
    Yu, Hui, Boyle, Theresa A., Zhou, Caicun, Rimm, David L., Hirsch, Fred R. · 2016 · Journal of Thoracic Oncology
  94. Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
    Keiichi Ota, Koichi Azuma, Akihiko Kawahara, Satoshi Hattori, Eiji Iwama, Junko Tanizaki, Taishi Harada, Koichiro Matsumoto, Koichi Takayama, Shinzo Takamori et al. · 2015 · Clinical Cancer Research
  95. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
    Raoul Andre Droeser, Christian Hirt, Carsten Thomas Viehl, Daniel M. Frey, Christian Andreas Nebiker, Xaver Huber, Inti Zlobec, Serenella Eppenberger‐Castori, Alexandar Tzankov, Raffaele Rosso et al. · 2013 · European Journal of Cancer
  96. Epigenetics in cancer stem cells
    Tan Boon Toh, Jhin Jieh Lim, Edward Kai‐Hua Chow · 2017 · Molecular Cancer
  97. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
    Thomas F. Gajewski, Seng‐Ryong Woo, Yuanyuan Zha, Robbert M. Spaapen, Yan Zheng, Leticia P. Corrales, Stefani Spranger · 2013 · Current Opinion in Immunology
  98. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
    Charles G. Drake, Evan J. Lipson, Julie Renee Brahmer · 2013 · Nature Reviews Clinical Oncology
  99. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
    Patrick J. Danaher, Sarah E. Warren, Rongze Olivia. Lu, Josue A. Samayoa, Amy H. Sullivan, Irena Pekker, Brett Wallden, Francesco Maria Marincola, Alessandra Cesano · 2018 · Journal for ImmunoTherapy of Cancer
  100. Injectable cryogel-based whole-cell cancer vaccines
    Sidi A. Bencherif, R. Warren Sands, Omar A. Ali, Aileen W. Li, Sarah A. Lewin, Thomas M. Braschler, Ting‐Yu Shih, Catia S. Verbeke, Deen Bhandu Bhatta, Glenn Dranoff et al. · 2015 · Nature Communications